Breast cancer susceptibility testing: Past, present and future

Expert Review of Anticancer Therapy

Volumn 6, Issue 8, 2006, Pages 1205-1214

  Goldberg, Jessica I ^a   Borgen, Patrick I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BRCA genes; Hereditary breast cancer; Hereditary ovarian cancer; Heterozygote; Tumor suppressor genes

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; ESTROGEN RECEPTOR; ONCOPROTEIN; PROGESTERONE RECEPTOR; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER RECURRENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CELL CYCLE; DNA DAMAGE; ECHOGRAPHY; EPIGENETICS; FAMILY HISTORY; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HEALTH SURVEY; HEREDITY; HETEROZYGOSITY; HUMAN; INHERITANCE; LIFESTYLE; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PHENOTYPE; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SALPINGOOOPHORECTOMY; SECONDARY PREVENTION;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MUTATION; OVARIAN NEOPLASMS;

EID: 33748110809     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.8.1205     Document Type: Review

References (76)

1. Lacroix M, Leclercq G. The "portrait" of hereditary breast cancer. Breast Cancer Res. Treat. 89(3), 297-304 (2005).
2. Chen S, Iversen ES, Friebel T et al. Characterization of BRCA1 BRCA2 mutations in a large United States sample. J. Clin. Oncol. 24(6), 863-871 (2006).
3. de Jong MM, Nolte IM, te Meerman GJ. et al. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J. Med. Genet. 39(4),225-242 (2002).
4. Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, asd other neoplasms. Science 205(4985), 1233-1238 (1990).
5. Waite KA, Eng C. Protean PTEN: form and function. Am. J. Hum. Genet. 70(4),829-844 (2002).
6. Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250 (4988),1684-1689 (1990).
7. Couch FJ, Kiousis S, Castilla LH et al. Characterization of 10 new polymorphic dinucleotide repeats and generation of a high-density microsatellite-based physical map of the BRCA1 region of chromosome 17q21. Genomics 24(3),419-424 (1994)
8. Cropp CS, Champeme MH, Lidereau R, Callahan R. Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted. Cancer Res. 53(23),5617-5619 (1993).
9. Miki Y, Swensen J, Shattuck-Eidens D. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182),66-71 (1994).
10. Futreal PA, Liu Q, Shattuck-Eidens D. et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266(5182), 120-122 (1994).
11. Wooster R, Neuhausen SL, Mangion J. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265(5181), 2088-2090 (1994).
12. Wooster R, Bignell G, Lancaster J. et al. Identification of the breast cancer susceptibility gene. Nature 378 (6559),789-792 (1995)
13. Tavtigian SV, Simard J, Rommens J et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. 12(3), 333-337 (1996).
14. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68(4)820-823 (1971).
15. Smith SA, Easton DF, Evans DG, Ponder BA. Allele lossed in the region 17q12-21 in familial breast and ovarian cancer involve the wildtype chromosome. Nat. Genet. 2(2), 128-131 (1992).
16. Collins N, McManus R, Wooster R et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 10(8),1673-1675 (1995).
17. Shattuck-Eidens D, Oliphant A, McClure M et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278 (15), 1242-1250 (1997).
18. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108(2), 171-182 (2002).
19. Welcsh PL, Lee MK, Gonzalez-Hernandez RM et al. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc. Natl Acad. Sci. USA 99(11), 7560-7565 (2002).
20. Narod SA, Foulkes WD. BRCA1 and BRCA2. 1994 and beyond. Nat. Rev. Cancer 4(9),665-676 (2004).
21. Welsch PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. 10 (7),705-713 (2001).
22. Liu Y, West SC. Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res. 4(1),9-13 (2002).
23. Yang H, Jeffrey PD, Miller J et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297(5588),1837-1848 (2002).
24. Honrado E, Benitez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod. Pathol. 18(10),1305-1320 (2005).
25. Hogervorst FB, Cornelis RS, Bout M et al. Rapid detection of BRCA1 mutations by the protien truncation test. Nat. Genet. 10 (2),208-212 (1995).
26. Andrulis IL, Anton-Culver H, Beck J et al. Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum. Mutat. 20(1),65-73 (2002).
27. Simard J, Tonin P, Durocher F et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat. Genet. 8(4),392-398 (1994).
28. Gorski B, Jakubowska A, Huzarski T et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int. J. Cancer 110(5),683-686 (2004).
29. Tulinius H, Olafsdottir GH, Sigvaldason H et al. The effect of a single BRCA2 mutation on cancer in Eceland J. Med. Genet. 39(7),457-462 (2002).
30. de Bock GH, Tollenaar RA, Papelard H et al. Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breasr cancer patients. Br. J. Cancer 85(9),1347-1350 (2001)
31. Einbeigi Z, Bergman A, Kindblom LG et al. A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur. J. Cancer 37(15),1904-1909 (2001).
32. Heimdal K, Maehle L, Apold J, Pedersen JC, Moller P. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Eur. J. Cancer 39(15),2205-2213 (2003).
33. Satagopan JM, Offit K, Foulkes W et al. The lifetime risks of breast cancer in Ashkenazi Jewish caries of BRCA1 and BRCA2 mutations. Cancer Epidemiol. Biomarkers Prev. 10(5),467-473 (2001).
34. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336(20),1401-1408 (1997).
35. Struewing JP, Abeliovich D, Peretz T et al. The carrier frequency of the BRCA1 185de1AG mutation is approximately 1 percent in Ashkenzi Jewish individuals. Nat. Genet. 11(2),198-200 (1995).
36. Oddoux C, Struewing JP, Clayton CM et al. The carrier frequency of the BRCA2 6174de1T mutation among Ashkenzi Jewish individuals is approximately 1%. Nat. Genet. 14(2), 188-190 (1996).
37. Newman B, Mu H, Butler LM et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279(12),915-921 (1998).
38. Kim SW, Lee CS, Fey JV, Borgen PI, Boyd J. Prevalence of BRCA2 mutations in a hospital based series of unselected breast cancer cases. J. Med. Genet. 42(1), E5 (2005).
39. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645), 643-646 (2003).
40. Antoniou AC, Pharoah PD, Narod S et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185de1AG and BRCA26174de1T mutations: a combined analysis of 22 population based studies. J. Med. Genet. 42(7), 602-603 (2005).
41. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72(5), 1117-1130 (2003).
42. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62 (3),676-689 (1998).
43. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet. 68 (2),410-419 (2001).
44. Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol. Biomarkers Prev. 14(1),20-26 (2005).
45. Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1 and BRCA2-related breast cancer. Semin. Surg. Oncol. 18(4),287-295 (2000).
46. Foulkes WD, Metcalfe K, Hanna W et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 98(8),1569-1577 (2003).
47. Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst. 95(19),1482-1485 (2003).
48. Arnes JB, Brunet JS, Stefansson I et al. Placenta cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin. Cancer Res. 11(11),4003-4011 (2005).
49. Rubin SC. BRCA-related ovarian carcinoma. Cancer 97(9),2127-2129 (2003).
50. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals J. Clin. Oncol. 20(6),1480-1490 (2002).
51. Hampe H, Sweet K, Westman JA, Offit K, Eng C. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J. Med. Genet. 41 (2),81-91 (2004).
52. Claus EB. Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians. Fam. Cancer 1(1-4), 197-206 (2001).
53. Green MJ, Botkin JR. "Genetic exceptionalism" in medicine: clarifying the differences between genetic and nongenetic tests. Ann. Int. Med. 138(7),571-575 (2003).
54. Walsh T, Casadei S, Coats KH et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12),1379-1054 (2006).
55. Ponder B. Genetic testing for cancer risk. Science 278(5340),1050-1054 (1997).
56. Cullinane CA, Lubinski J, Neuhausen SL et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation Int. J. Cancer 117(6),988-991 (2005).
57. Jernstrom H, Lubinski J, Lynch HT et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J.Natl Cancer Inst. 96(14),1094-1098 (2004).
58. Milne RL, Knight JA, John EM et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol. Biomarkers Prev. 14(2),350-356 (2005).
59. Ghadirian P, Lubinski J, Lynch H et al. Smoking and the risk of breast cancer among carriers of BRCA mutations. Int. J. Cancer 110(3),413-416 (2004).
60. Nkondjock A, Ghadirian P, Kotsopoulos J et al. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int. J. Cancer 118(1),103-107 (2006).
61. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol. 22(6), 1055-1062 (2004).
62. Meijers-Heijboer H, van Geel B, van Putten WL et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 345(3), 159-164 (2001).
63. Garcia-Etienne CA, Borgen PI. Update on the indications for nipple-sparing mastectomy. J. Support Oncol. 4, 225-230 (2006).
64. Hartmann LC, Sellers TA, Schaid DJ et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl Cancer Inst. 93 (21), 1633-1637 (2001).
65. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346(21), 1609-1615 (2002).
66. Eisen A, Lubinski J, Klijn J et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J. Clin. Oncol. 23(30), 7491-7496 (2005).
67. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 97(22), 1652-1662 (2005).
68. King MC, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286(18), 2251-2256 (2001).
69. Brekelmans CT, Seynaeve C, Bartels CC et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J. Clin. Oncol. 19(4), 924-930 (2001).
70. Carney PA, Miglioretti DL, Yankaskas BC et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann. Int. Med. 138(3), 168-175 (2003).
71. Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292(11), 1317-1325 (2004).
72. Robson ME, Offit K. Breast MRI for women with hereditary cancer risk. JAMA 292(11), 1368-1370 (2004).
73. Newman LA, Kuerer HM. Advances in breast conservation therapy. J. Clin. Oncol. 23(8), 1685-1697 (2005).
74. Haffty BG, Harrold E, Khan AJ et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359(9316), 1471-1477 (2002).
75. Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radiotheraphy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J. Natl Cancer Inst. 96(2),115-121 (2004).
76. Pierce LJ, Levin AM, Rebbeck TR et al. Ten-year multi-institutional results of breast-conserving surgery and radiotheraphy in BRCA1/ 2-associated stage I/II breast cancer. J. Clin. Oncol. 24(16), 2437-2443 (2006).